Randomised participants who received at least one dose in all studies are included in the safety analysis. However, each study had to meet prespecified criteria of having at least five cases eligible for inclusion in the primary outcome before a study was included in efficacy analyses. Neither COV...
“In that case you’ll see different products used as third or fourth or fifth boosters,” Smith said. “We need to be thinking through, should it be the same produced we received for our first or second dose, or can we start to mix and match? This is beginning to ...
Data revealed that one dosing regimen showed a 90% efficacy when given as a half dose followed by a full dose at least one month apart. A second dosing regimen showed a 62% efficacy when given as two full doses at least one month apart, averaging to a 70% efficacy, acc...
Overall, PREVENT-19 achieved its primary endpoint of efficacy in preventing polymerase chain reaction (PCR)-confirmed, symptomatic mild, moderate, or severe COVID-19 with onset at least seven days after the second dose. Novavax also submitted the manuscript, “Efficacy and Safety...
In this trial, AZD0780 delivered a statistically significant LDL-C reduction of 52% on top of standard-of-care statin resulting in a 78% reduction from baseline. This efficacy, combined with the excellent bioavailability of the compound means that we can dose once daily with no food effect or...
BORA and GREGALE. The two pivotal trials SIROCCO and CALIMA, are randomised, double-blinded, parallel-group, placebo-controlled trials designed to evaluate the efficacy and safety of a regular, subcutaneous administration of Fasenra (fixed 30mg dose) for up to 56-weeks in exacerbation-prone adult...
Doffman S, Dosanjh D, Sadiq MW. Phase 1 safety and efficacy of AZD8630/AMG 104 inhaled anti-TSLP in healthy volunteers and patients with asthma on medium-high dose inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) with elevated baseline fractional exhaled nitric oxide (Fe...
and that can improve the safety profile. And third, the shorter manufacturing time delivers fitter T-cells, and this potentially improves the efficacy of this CAR-T. This proposed acquisition also enriches our growing pipeline of cell therapies with GC012F, a novel clinical-stage dual ...
With the approval of Enhertu, patients in China with HER2-positive metastatic gastric cancer will now have an important anti-HER2 treatment option that has demonstrated clinically meaningful efficacy following progression on previous therapies.” In the Phase II trial, a 6.4 mg/kg dose of Enhe...
The Anglo-Swedish company is aiming to deliver 100 million doses by June, a third of the original amount it committed to. READ MORE: Anxiety surge over life after lockdown Seville's oranges are key to green future PODCAST: Are we alone in the universe?